Translation of genomics and epigenomics in prostate cancer： progress and promising directions

During the last several years, exciting discoveries have been madein prostate cancer （PCa） as a result of significant advances in genomic technology and information. For example, using genome-wide association studies, more than 100 inherited genetic variants associated with PCa risk have been identi...

Full description

Saved in:
Bibliographic Details
Published inAsian journal of andrology Vol. 18; no. 4; pp. 503 - 504
Main Authors Liu, Wennuan, Xu, Jianfeng
Format Journal Article
LanguageEnglish
Published China Wolters Kluwer - Medknow Publications 01.07.2016
Medknow Publications and Media Pvt. Ltd
Medknow Publications & Media Pvt. Ltd
Medknow Publications & Media Pvt Ltd
Wolters Kluwer Medknow Publications
Subjects
Biopsy
Cancer therapies
Care and treatment
Decision making
Deoxyribonucleic acid
DNA
Epigenetics
Epigenomics
Gene expression
Genetic aspects
Genomes
Genomics
Humans
Male
Medical prognosis
Mens health
Metastasis
Methods
Mortality
Mutation
Population
Prostate cancer
Prostatic Neoplasms - genetics
Quality of life
Risk factors
Tumors
全基因组
前列腺癌
前列腺肿瘤
基因组学
基因组技术
翻译
表观
遗传变异
Online AccessGet full text
ISSN1008-682X
1745-7262
1745-7262
DOI10.4103/1008-682X.182820

Cover

More Information
Summary:During the last several years, exciting discoveries have been madein prostate cancer （PCa） as a result of significant advances in genomic technology and information. For example, using genome-wide association studies, more than 100 inherited genetic variants associated with PCa risk have been identified. Similarly, with the use of next-generation sequencing, various types of recurrent somatic DNA alterations in prostate tumors have been revealed. Some of these discoveries have potential clinical application to supplement existing tools for better decision-making regarding the need for screening, biopsy, and treatment of PCa. However, because of the complexity of these genomic findings and incomplete understanding of the genetics of this multifactorial disease, this potential has not yet been fully realized.
Bibliography:During the last several years, exciting discoveries have been madein prostate cancer （PCa） as a result of significant advances in genomic technology and information. For example, using genome-wide association studies, more than 100 inherited genetic variants associated with PCa risk have been identified. Similarly, with the use of next-generation sequencing, various types of recurrent somatic DNA alterations in prostate tumors have been revealed. Some of these discoveries have potential clinical application to supplement existing tools for better decision-making regarding the need for screening, biopsy, and treatment of PCa. However, because of the complexity of these genomic findings and incomplete understanding of the genetics of this multifactorial disease, this potential has not yet been fully realized.
31-1795/R
SourceType-Scholarly Journals-1
content type line 14
content type line 23
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1008-682X
1745-7262
1745-7262
DOI:10.4103/1008-682X.182820